J Am Dent Assoc. 2024 Jan;155(1):7-16.e7. doi: 10.1016/j.adaj.2023.10.002. Epub 2023 Nov 19.
Despite decreases in opioid prescribing from 2016 through 2019, some dentists (general, specialists, oral and maxillofacial surgeons) in the United States continue to prescribe opioids at high rates. The authors' objective was to define dentists' trajectories of opioid prescribing.
The authors identified actively prescribing dentists from the IQVIA Longitudinal Prescription data set, from 2015 through 2019. Group-based trajectory modeling identified opioid prescribing trajectories on the basis of dentists' annual prescribing rates for the overall sample (model 1) and for high prescribers (model 2). The authors used χ or Mann-Whitney U tests to characterize the model 2 trajectory groups.
In model 1 (n = 199,145 prescribers), group-based trajectory modeling identified 8 trajectories that were grouped into 5 categories. A total of 14.8% were nonprescribers who composed less than 1% of all prescriptions, low prescribers (3 groups; 46.0%) prescribed at low rates (2015: 5.5%-16.9%; 2019: 1.5%-11.9%), decliners (7.3%) decreased prescribing rapidly (2015: 29.4%; 2019: 5.1%), moderately high prescribers (2 groups; 28.5%) prescribed moderately (2015: 28.7% and 39.2%; 2019: 18.1% and 28.8%), and consistently high prescribers (3.4%) prescribed at high rates (2015: 54.6%; 2019: 44.7%). In model 2, from consistently high prescribers (n = 6,845), 4 trajectories were identified. Of these 4 groups, 1 group (7.5%) declined prescribing rapidly. The groups did not differ meaningfully; however, the rapid decliners included fewer oral and maxillofacial surgeons (13.0% vs 18.4%), saw more Medicaid patients (2.5% vs 1.0%), and had higher opioid prescribing rates in 2015 (95.5% vs 91.6%) (P < .001 for all).
The authors identified variations in dentists' opioid prescribing rates. Although 60% of dentists decreased prescribing rates by 30% through 83%, 3.4% of dentists consistently prescribed at high rates.
Some dentists continue to prescribe opioids at high levels, indicating that additional information is needed to better inform policy and clinical decision making.
尽管从 2016 年到 2019 年阿片类药物的处方量有所减少,但美国仍有一些牙医(全科、专科、口腔颌面外科医生)继续大量开阿片类药物。作者的目的是确定牙医开阿片类药物的轨迹。
作者从 IQVIA 纵向处方数据集中确定了正在积极开处方的牙医,数据时间为 2015 年至 2019 年。基于所有样本(模型 1)和高处方者(模型 2)的年度处方率,采用基于群组的轨迹建模来确定阿片类药物的处方轨迹。作者使用 χ 或曼-惠特尼 U 检验来描述模型 2 轨迹组。
在模型 1(n=199145 名处方者)中,基于群组的轨迹建模确定了 8 个轨迹,这些轨迹分为 5 个类别。非处方者共 14.8%,他们开具的处方不到所有处方的 1%,低处方者(3 组;46.0%)以低速率开处方(2015 年:5.5%-16.9%;2019 年:1.5%-11.9%),下降者(7.3%)迅速减少处方(2015 年:29.4%;2019 年:5.1%),中度高处方者(2 组;28.5%)以中度剂量开处方(2015 年:28.7%和 39.2%;2019 年:18.1%和 28.8%),以及始终高处方者(3.4%)以高剂量开处方(2015 年:54.6%;2019 年:44.7%)。在模型 2 中,从始终高处方者(n=6845)中确定了 4 个轨迹。在这 4 个组中,有 1 个组(7.5%)迅速减少了处方。这些组之间没有显著差异;然而,快速下降者包括较少的口腔颌面外科医生(13.0%比 18.4%),看更多的医疗补助患者(2.5%比 1.0%),并且在 2015 年的阿片类药物处方率更高(95.5%比 91.6%)(均 P<.001)。
作者发现牙医阿片类药物处方率存在差异。尽管 60%的牙医将处方减少了 30%至 83%,但仍有 3.4%的牙医持续开高剂量的阿片类药物。
一些牙医继续大量开阿片类药物,这表明需要提供更多信息,以更好地为政策和临床决策提供信息。